EGFR and non-small cell lung carcinoma: The results concerning the long-term OS confirmed that the median OS was significantly higher for the osimertinib arm (38.6 months) than the EGFR-TKIs arm (31.8 months), further suggesting osimertinib as a novel standard of care for NSCLC patients with EGFR-activating mutations [63].